Member Post

 

A hospital in Paris just announced “statistically significant clinical improvement” in Covid-19 patients using a drug called tocilizumab (aka Actemra). Tocilizumab is a monoclonal antibody that targets the IL-6 receptor, which is a signaling molecule in the immune system. In other words, the drug actually inhibits a specific part of the immune response, in this […]

Join Ricochet!

This is a members-only post on Ricochet's Member Feed. Want to read it? Join Ricochet’s community of conservatives and be part of the conversation. Join Ricochet for Free.

There is 1 comment.
But you can't read it because you're not signed in!

Become a member to read the comments and join the conversation. Or sign in if you're already a member.
Become a member to read the comments and join the conversation. Or sign in if you're already a member.